FDA accepts priority review of gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urogenital gonorrhea in patients 12 years and older.
The FDA has granted priority review to expand flibanserin (Addyi; Sprout Pharmaceuticals) use to postmenopausal women, potentially broadening access to treatment for hypoactive sexual desire disorder.
The FDA has approved Visby Medical’s at-home sexually transmitted infection test, allowing women to screen for chlamydia, gonorrhea, and trichomoniasis without a prescription.
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Sexual Health and Wellness Consortium
The Sexual Health and Wellness Consortium features a variety of informative videos, articles, podcasts, polls, and quizzes to help you better care for your patients as they navigate their sexual health and wellness journey.